Avantor Investor Conference Presentation Deck
Avantor's role in helping to end the COVID-19 pandemic
Well-positioned to address dynamics
ור
Im
SUPPORT FOR FAST-TRACK DEVELOPMENT
OF THERAPIES AND VACCINES
Key participant in Operation Warp Speed
Significant role in development and scale up
- Content across all vaccine modalities
Clinical trial support
ENABLE FAST, RELIABLE COVID-19 TESTING
Onsite supply chain management at testing facilities
-
- Sample preparation, kitting for PCR tests
Serological and antigen test kits
PROTECT SAFETY OF PEOPLE, PRODUCTS
AND PROCESSES
Full suite of over 100,000 safety and industrial
products
Head-to-toe protection
Navantor™
1. FY20 estimate and management estimates
Safety
2020E¹
~$250-
$300M
Diagnostics
REVENUE
Vaccines &
Therapies
Safety
2021E¹
$250-
$350M+
Diagnostics
Vaccines &
Therapies
39th Annual J.P. Morgan Healthcare Conference
18View entire presentation